Pei Yun Tsai, Ph.D.
About Pei Yun Tsai, Ph.D.
Pei Yun Tsai, Ph.D., is a Senior Scientist specializing in immunotherapy for T cell receptors at ElevateBio. With extensive experience in oncology and gene editing techniques, Dr. Tsai has contributed to the preclinical development of various cell therapies.
Work at ElevateBio
Pei Yun Tsai, Ph.D., serves as a Senior Scientist in Immunotherapy for TCR at ElevateBio. She has been with the company since 2022, focusing on the development of innovative therapies in the field of immunotherapy. Her role involves leveraging her expertise in T cell receptor (TCR) technologies to advance therapeutic options for patients with various malignancies.
Education and Expertise
Pei Yun Tsai holds a Doctor of Philosophy (Ph.D.) in Biological Sciences from Harvard T.H. Chan School of Public Health, where she studied cancer metabolism from 2013 to 2019. She also earned a Master's degree in Virology from National Taiwan University (2010-2012) and a Bachelor's degree in Life Science from Fu Jen Catholic University (2006-2010). Her educational background supports her expertise in oncology and immunotherapy.
Background
Pei Yun Tsai began her academic journey at Fu Jen Catholic University, where she completed her Bachelor's degree in Life Science. She then pursued a Master's degree in Virology at National Taiwan University. Following her master's studies, she gained practical experience through a summer internship at the University of California, Davis, in 2011. Her professional career includes roles at Simcere Innovation, Takeda, and currently ElevateBio.
Professional Experience
Pei Yun Tsai has accumulated significant experience in the field of immunotherapy. Prior to her current position at ElevateBio, she worked as a Scientist II at Simcere Innovation from 2020 to 2021 and as a Scientist in Cell Therapy at Takeda from 2021 to 2022. Her work has included developing assays to evaluate immune cell function and utilizing CRISPR/CAS9 and other gene editing techniques to enhance T cell function.
Research and Development Focus
Pei Yun Tsai specializes in the preclinical development of CAR-T, TCR-T, and CAR-NK therapies aimed at treating both solid and hematological malignancies. Her research contributions include developing assays for immune cell evaluation and employing gene editing technologies to create hypoimmune cells, which are critical for advancing cancer therapies.